FibroBiologics Files 2024 Second Quarter Report
FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, with the U.S. Securities and Exchange Commission. The company specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. FibroBiologics boasts a portfolio of over 150 issued and pending patents in this field. The quarterly report, which provides detailed financial and operational information for the second quarter of 2024, is now available for public viewing through a link on the company's investor relations website.
FibroBiologics, Inc. (Nasdaq: FBLG), un'azienda biotecnologica in fase clinica, ha presentato il suo Rapporto Trimestrale sul Modulo 10-Q per il trimestre conclusosi il 30 giugno 2024, alla Securities and Exchange Commission degli Stati Uniti. L'azienda si specializza nello sviluppo di terapie e potenziali cure per malattie croniche utilizzando fibroblasti e materiali derivati dai fibroblasti. FibroBiologics vanta un portafoglio di oltre 150 brevetti concessi e in attesa in questo settore. Il rapporto trimestrale, che fornisce informazioni dettagliate finanziarie e operative per il secondo trimestre del 2024, è ora disponibile per la consultazione pubblica tramite un link sul sito web delle relazioni con gli investitori dell'azienda.
FibroBiologics, Inc. (Nasdaq: FBLG), una compañía biotecnológica en etapa clínica, ha presentado su Informe Trimestral en el Formulario 10-Q para el trimestre terminado el 30 de junio de 2024, ante la Comisión de Bolsa y Valores de EE. UU. La compañía se especializa en el desarrollo de terapias y posibles curas para enfermedades crónicas utilizando fibroblastos y materiales derivados de fibroblastos. FibroBiologics cuenta con un portafolio de más de 150 patentes emitidas y pendientes en este campo. El informe trimestral, que proporciona información financiera y operativa detallada para el segundo trimestre de 2024, ya está disponible para su visualización pública a través de un enlace en el sitio web de relaciones con inversionistas de la compañía.
FibroBiologics, Inc. (Nasdaq: FBLG), 임상 단계의 생명공학 회사,가 2024년 6월 30일로 종료된 분기 동안의 10-Q 양식 분기 보고서를 미국 증권 거래 위원회에 제출했습니다. 이 회사는 섬유아세포와 섬유아세포 유래 물질을 사용하여 만성 질환에 대한 치료제 및 잠재적 치료법 개발을 전문으로 하고 있습니다. FibroBiologics는 이 분야에서 150개 이상의 발행 및 대기 중인 특허 포트폴리오를 보유하고 있습니다. 2024년 2분기에 대한 자세한 재무 및 운영 정보가 포함된 분기 보고서는 이제 회사의 투자자 관계 웹사이트의 링크를 통해 공개적으로 열람 가능합니다.
FibroBiologics, Inc. (Nasdaq: FBLG), une entreprise biopharmaceutique en phase clinique, a déposé son Rapport Trimestriel sur le Formulaire 10-Q pour le trimestre se terminant le 30 juin 2024, auprès de la Commission des valeurs mobilières des États-Unis. L'entreprise se spécialise dans le développement de thérapies et de traitements potentiels pour les maladies chroniques, en utilisant des fibroblastes et des matériaux dérivés de fibroblastes. FibroBiologics possède un portefeuille de plus de 150 brevets délivrés et en attente dans ce domaine. Le rapport trimestriel, qui fournit des informations financières et opérationnelles détaillées pour le deuxième trimestre de 2024, est désormais disponible pour consultation publique via un lien sur le site web des relations avec les investisseurs de l'entreprise.
FibroBiologics, Inc. (Nasdaq: FBLG), ein biopharmazeutisches Unternehmen in klinischer Phase, hat seinen Quartalsbericht im Formular 10-Q für das zum 30. Juni 2024 abgeschlossene Quartal bei der US-amerikanischen Börsenaufsicht eingereicht. Das Unternehmen ist auf die Entwicklung von Therapeutika und potenziellen Heilmitteln für chronische Erkrankungen spezialisiert, die Fibroblasten und fibrolastenabgeleitete Materialien nutzen. FibroBiologics verfügt über ein Portfolio von über 150 erteilten und angemeldeten Patenten in diesem Bereich. Der Quartalsbericht, der detaillierte finanzielle und betriebliche Informationen für das zweite Quartal 2024 bietet, ist nun über einen Link auf der Investor-Relations-Website des Unternehmens öffentlich einsehbar.
- Portfolio of 150+ issued and pending patents
- Clinical-stage biotechnology company status
- Focus on potential cures for chronic diseases
- None.
HOUSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, with the U.S. Securities and Exchange Commission.
The filing can be viewed through a link on FibroBiologics’ website at https://ir.fibrobiologics.com/sec-filings/quarterly-reports.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
212-845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What is FibroBiologics' stock symbol?
When did FibroBiologics file its 2024 Q2 report?
What is FibroBiologics' main focus in biotechnology?
How many patents does FibroBiologics have?
